Skip to main content

Table 1 Baseline characteristics of patients with and without diabetes (medical history of diabetes or concomitant use of antidiabetic treatment) across three phase III studies

From: Interleukin-6 receptor blockade or TNFα inhibition for reducing glycaemia in patients with RA and diabetes: post hoc analyses of three randomised, controlled trials

  With diabetes (N = 184) Without diabetes (N = 1928) p value
Age (years)    < 0.0001
 Mean (SD) 56.5 (9.4) 51.0 (12.1)  
Sex, n (%)    0.3348
 Female 146 (79.3) 1585 (82.2)  
 Male 38 (20.7) 343 (17.8)  
Race, n (%)    0.0907
 Caucasian/White 147 (79.9) 1607 (83.4)  
 Black 8 (4.3) 44 (2.3)  
 Asian 15 (8.2) 99 (5.1)  
 Other 14 (7.6) 178 (9.2)  
Weight (kg)    < 0.0001
 Mean (SD) 84.08 (21.59) 74.04 (18.76)  
Body mass index (kg/m2)    < 0.0001
 Mean (SD) 32.18 (7.40) 28.04 (6.38)  
Duration of RA since diagnosis (years)    0.6294
 Mean (SD) 9.82 (8.81) 9.51 (8.44)  
Rheumatoid factor, n (%)    0.0964
 Positive 136 (74.3) 1517 (79.5)  
 Negative 47 (25.7) 390 (20.5)  
Anti CCP antibody, n (%)    0.0593
 Positive 143 (77.7) 1587 (83.2)  
 Negative 41 (22.3) 320 (16.8)  
Tender joint count (0–68)    0.0017
 Mean (SD) 30.97 (15.92) 27.11 (14.11)  
Swollen joint count (0–66)    0.0185
 Mean (SD) 19.72 (11.90) 17.57 (10.02)  
HAQ-DI (0–3)    0.0010
 Mean (SD) 1.82 (0.66) 1.66 (0.63)  
CRP (mg/L)    0.3210
 Mean (SD) 24.90 (29.39) 22.67 (24.22)  
Oral glucocorticosteroid use, n (%) 119 (64.7) 1177 (61.0) 0.3344
 Mean (SD) prednisone equivalent dose, mg 6.6 (2.63) 6.6 (2.68) 0.7462
Hydroxychloroquine use, n (%) 4 (2.2) 33 (1.7) > 0.9999
Antidiabetic medication use, n (%) 143 (77.7) NR NR
 Any noninsulin blood glucose-lowering drug, n (%)a 85 (46.2) NR NR
 ≥ 2 noninsulin blood glucose-lowering drugs, n (%)b 32 (17.4) NR NR
 Any insulin and analogue without oral blood glucose lowering drug, n (%) 13 (7.1) NR NR
 Any insulin and analogue plus oral blood glucose lowering drug, n (%) 14 (7.6) NR NR
  1. Percentages are calculated using number of patients assessed as denominator
  2. p values are based on t test for continuous variables and chi-square test if frequency in all cells ≥ 5 and Fisher exact test if frequency in at least one cell < 5, for categorical variables
  3. CCP cyclic citrullinated peptide, CRP C-reactive protein, HAQ-DI Health Assessment Questionnaire-Disability Index, Number number of patients assessed, NR not relevant, RA rheumatoid arthritis, SD standard deviation
  4. aExcluding insulins, monotherapy
  5. bExcluding insulins